Dataset Information

Contribution of ShkA dysregulation to the cdG0 phenotype

ABSTRACT: The ShkA-ShpA-TacA phosphorelay regulates stalk biogenesis and G1-S phase transition in Caulobacter crescentus. Histidine kinase activity of ShkA is c-di-GMP dependent and a strain lacking c-di-GMP (cdG0) shows a number of phenotypic aberrations. In this project, we aim at disentangling the contribution of ShkA-ShpA-TacA pathway dysregulation to the cdG0 phenotype by profiling the proteomes of mutants that constitutively activate or deactivate TacA target gene expression.

INSTRUMENT(S): LTQ Orbitrap

ORGANISM(S): Caulobacter Sp. 736

TISSUE(S): Cell Suspension Culture, Permanent Cell Line Cell

SUBMITTER: Alexander Schmidt

LAB HEAD: Alexander Schmidt

PROVIDER: PXD012739 | Pride | 2019-12-16

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	001_shkA-ex1_A16 (F055216).mzid_001_shkA-ex1_A16_(F055216).pride.mgf.gz	Mzid
	001_shkA-ex1_A16 (F055216).pride.mztab.gz	Mztab
	001_shkA-ex1_A16.raw	Raw
	001_shkA-ex1_A16F055216.mzid.gz	Mzid
	001_shkA-ex1_A16F055216.mzid_001_shkA-ex1_A16_F055216.MGF	Mzid

Items per page:

1 - 5 of 30

Publications

Precise timing of transcription by c-di-GMP coordinates cell cycle and morphogenesis in Caulobacter.

Kaczmarczyk Andreas A Hempel Antje M AM von Arx Christoph C Böhm Raphael R Dubey Badri N BN Nesper Jutta J Schirmer Tilman T Hiller Sebastian S Jenal Urs U

Nature communications 20200210 1

Bacteria adapt their growth rate to their metabolic status and environmental conditions by modulating the length of their G1 period. Here we demonstrate that a gradual increase in the concentration of the second messenger c-di-GMP determines precise gene expression during G1/S transition in Caulobacter crescentus. We show that c-di-GMP stimulates the kinase ShkA by binding to its central pseudo-receiver domain, activates the TacA transcription factor, and initiates a G1/S-specific transcription ...[more]

PMID: 32041947

Similar Datasets

Project description:Maintaining skeletal muscle mass is of high importance as muscle atrophy like during sarcopenia or cachexia lead to a decrease in independence and a higher risk of morbidity and mortality. A leading compound in the treatment against ageing and cancer is rapamycin, an inhibitor of mechanistic target of rapamycin complex 1 (mTORC1). Whether the treatment with mTORC1 inhibitors would work at a cost of losing muscle mass is unclear, as most studies have been focusing on the role of mTORC1 specifically during hypertrophy. In order to answer this question we developed an inducible muscle specific knockout mouse model in which raptor can be ablated during adulthood to eliminate mTORC1 activity. We analysed the muscles after different time points and found that after 3 months the mice showed a fiber shift towards slower fiber types, a loss in oxidative capacity but only very few myopathic features. After 5 months the myopathic features became more apparent, however it did not largely affect the ex vivo muscle force. Surprisingly despite the myopathy we did not see a significant loss of muscle mass even after 5 months, that we hypothesised based on mTORC1s central role in protein synthesis. We assume that the myopathy after long-term mTORC1 inactivation is mostly a result of secondary effects through the loss of mitochondria, alterations in metabolism and in cytoskeletal components. In conclusion, during skeletal muscle maintenance mTORC1 is more essential for metabolic processes than it is for maintaining basal muscle mass.Maintaining skeletal muscle mass is of high importance as muscle atrophy like during sarcopenia or cachexia lead to a decrease in independence and a higher risk of morbidity and mortality. A leading compound in the treatment against ageing and cancer is rapamycin, an inhibitor of mechanistic target of rapamycin complex 1 (mTORC1). Whether the treatment with mTORC1 inhibitors would work at a cost of losing muscle mass is unclear, as most studies have been focusing on the role of mTORC1 specifically during hypertrophy. In order to answer this question we developed an inducible muscle specific knockout mouse model in which raptor can be ablated during adulthood to eliminate mTORC1 activity. We analysed the muscles after different time points and found that after 3 months the mice showed a fiber shift towards slower fiber types, a loss in oxidative capacity but only very few myopathic features. After 5 months the myopathic features became more apparent, however it did not largely affect the ex vivo muscle force. Surprisingly despite the myopathy we did not see a significant loss of muscle mass even after 5 months, that we hypothesised based on mTORC1s central role in protein synthesis. We assume that the myopathy after long-term mTORC1 inactivation is mostly a result of secondary effects through the loss of mitochondria, alterations in metabolism and in cytoskeletal components. In conclusion, during skeletal muscle maintenance mTORC1 is more essential for metabolic processes than it is for maintaining basal muscle mass.